[Phase I study with LH-RH agonist, ICI 118630].
A single shot of 250 micrograms LH-RH agonist, ICI 118630 (Zoladex), was subcutaneously administered to four healthy male volunteers to investigate the safety and endocrinal effect of the drug. The safety of the drug was confirmed because no clinical problems in vital sign and general clinical tests were observed. The endocrinal reactions of LH, FSH and testosterone in blood were also observed proving that the drug was the LH-RH agonist.
D002064:Buserelin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D004341:Drug Evaluation; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology* / Q000633:toxicity; D017273:Goserelin; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D013739:Testosterone / Q000097:blood
D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin